Transcatheter Replacement of Transcatheter Versus Surgically Implanted Aortic Valve Bioprostheses

• Published in: Journal of the American College of Cardiology 2021-01, Vol.77 (1), p.1-14
• Main Authors: Landes, Uri, Sathananthan, Janarthanan, Witberg, Guy, De Backer, Ole, Sondergaard, Lars, Abdel-Wahab, Mohamed, Holzhey, David, Kim, Won-Keun, Hamm, Christian, Buzzatti, Nicola, Montorfano, Matteo, Ludwig, Sebastian, Conradi, Lenard, Seiffert, Moritz, Guerrero, Mayra, El Sabbagh, Abdallah, Rodés-Cabau, Josep, Guimaraes, Leonardo, Codner, Pablo, Okuno, Taishi, Pilgrim, Thomas, Fiorina, Claudia, Colombo, Antonio, Mangieri, Antonio, Eltchaninoff, Helene, Nombela-Franco, Luis, Van Wiechen, Maarten P H, Van Mieghem, Nicolas M, Tchétché, Didier, Schoels, Wolfgang H, Kullmer, Matthias, Tamburino, Corrado, Sinning, Jan-Malte, Al-Kassou, Baravan, Perlman, Gidon Y, Danenberg, Haim, Ielasi, Alfonso, Fraccaro, Chiara, Tarantini, Giuseppe, De Marco, Federico, Redwood, Simon R, Lisko, John C, Babaliaros, Vasilis C, Laine, Mika, Nerla, Roberto, Castriota, Fausto, Finkelstein, Ariel, Loewenstein, Itamar, Eitan, Amnon, Jaffe, Ronen, Ruile, Philipp, Neumann, Franz J, Piazza, Nicolo, Alosaimi, Hind, Sievert, Horst, Sievert, Kolja, Russo, Marco, Andreas, Martin, Bunc, Matjaz, Latib, Azeem, Godfrey, Rebecca, Hildick-Smith, David, Chuang, Ming-Yu A, Blanke, Philipp, Leipsic, Jonathon, Wood, David A, Nazif, Tamim M, Kodali, Susheel, Barbanti, Marco, Kornowski, Ran, Leon, Martin B, Webb, John G
• Format: Article
• Language: English
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2020.10.053

Surgical aortic valve replacement and transcatheter aortic valve replacement (TAVR) are now both used to treat aortic stenosis in patients in whom life expectancy may exceed valve durability. The choice of initial bioprosthesis should therefore consider the relative safety and efficacy of potential subsequent interventions. The aim of this study was to compare TAVR in failed transcatheter aortic valves (TAVs) versus surgical aortic valves (SAVs). Data were collected on 434 TAV-in-TAV and 624 TAV-in-SAV consecutive procedures performed at centers participating in the Redo-TAVR international registry. Propensity score matching was applied, and 330 matched (165:165) patients were analyzed. Principal endpoints were procedural success, procedural safety, and mortality at 30 days and 1 year. For TAV-in-TAV versus TAV-in-SAV, procedural success was observed in 120 (72.7%) versus 103 (62.4%) patients (p = 0.045), driven by a numerically lower frequency of residual high valve gradient (p = 0.095), ectopic valve deployment (p = 0.081), coronary obstruction (p = 0.091), and conversion to open heart surgery (p = 0.082). Procedural safety was achieved in 116 (70.3%) versus 119 (72.1%) patients (p = 0.715). Mortality at 30 days was 5 (3%) after TAV-in-TAV and 7 (4.4%) after TAV-in-SAV (p = 0.570). At 1 year, mortality was 12 (11.9%) and 10 (10.2%), respectively (p = 0.633). Aortic valve area was larger (1.55 ± 0.5 cm vs. 1.37 ± 0.5 cm ; p = 0.040), and the mean residual gradient was lower (12.6 ± 5.2 mm Hg vs. 14.9 ± 5.2 mm Hg; p = 0.011) after TAV-in-TAV. The rate of moderate or greater residual aortic regurgitation was similar, but mild aortic regurgitation was more frequent after TAV-in-TAV (p = 0.003). In propensity score-matched cohorts of TAV-in-TAV versus TAV-in-SAV patients, TAV-in-TAV was associated with higher procedural success and similar procedural safety or mortality.